Medication Use, Safety, and Evidence Project (MUSE)
HSS Investigators: Susan Andrade, Robin Clark
Funding Agency: This project is being conducted as part of an FDA-required postmarketing study for extended-release and long-acting opioid analgesics being implemented by the Opioid Postmarketing Consortium (OPC) consisting of the following companies: Allergan; Collegium Pharmaceutical, Inc.; Daiichi Sankyo, Inc.; Depomed, Inc.; Egalet Corporation; Endo Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mallinckrodt, Inc.; Pernix Therapeutics Holdings, Inc.; Pfizer, Inc.; Purdue Pharma, LP.; West-Ward Pharmaceuticals Corp.
Status: Ongoing
Project Overview: The MUSE study, a prospective investigation of the risks of opioid misuse, abuse, and addiction among patients treated with extended-release/long acting (ER/LA) opioids for the treatment of chronic pain. The primary objective is to quantify the serious risks of misuse, abuse, and addiction associated with long-term use of opioid analgesics for management of chronic pain among patients newly prescribed ER/LA opioid products. This multi-site research study is comprised of both a prospective longitudinal study that will estimate the incidence of misuse, abuse and addiction associated with long-term use of ER/LA opioids for chronic pain, and a cross-sectional study that will estimate the prevalence of misuse, abuse and addition associated with long-term use of opioids.